Clinical study of combined determination of CYFRA21-1, CEA, NSEin the patients with lung c ancer

Xiumu JIN,Wenhui XIE,Zhichang YU,Peiling ZHANG
DOI: https://doi.org/10.3321/j.issn:0253-3219.2000.11.011
2000-01-01
Nuclear Techniques
Abstract:hree tumor markers or CEA, CYFRA21-1 and NSE were assayed in 239 cases with lung cancer (adenocarcinoma 129, squamous-cel l carcinoma 59, small cell lung cancer 35, mixed type of adenocarcinoma and squamous-cell carcinoma 16) and 66 cases with benign lung disease. The p ositive rate of CEA, CYFRA21-1 and NSE for detecting lung cancer were 51.4%, 43.5% and 48.1% respectively. It seemed there was a relationship betwee n the sensitivity and the pathologic patterns of lung cancer. The highest diagnostic sensitivities were 76.3% for CYFRA21-1 in the detection of squa mous-cell carcinoma, 57.4% for CEA in adenocarcinoma and 94.3% for NSE in the small cell lung cancer respectively. In 49 cases with pleural effusion (adenocarcinoma 27, small cell lung cancer 7, benign disease 15), three tumor markers in serum and pleural fluid were both measued. The results ind icated that the sensitivity of the CEA and CYFRA21-1 in pleural fluid in patients with adenocarcinoma was superior to serum. The detection of the NS E in pleural fluid was a very reliable method in diagnosing the small cell lung cancer. The sensitivity and specificity of CEA, CYFRA21-1 and NSE i n different pathologic patterns of lung cancer was compared and also the false positive and false negative in benign lung disease. Moreover, the cli nical role and necessity of combined determination were also discussed.
What problem does this paper attempt to address?